Reproductive system cancer

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This study tests whether taking probiotic supplements can improve the gut and vaginal microbiome in women with advanced or recurrent ovarian cancer who are receiving platinum-based chemotherapy. About 161 participants will be randomly assigned to receive either probiotics or a pl…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This phase 2 trial tests a drug called FG-3246, which is designed to seek out and attack prostate cancer cells that have a specific marker (CD46) on their surface. The study will enroll 75 men with metastatic castration-resistant prostate cancer that has worsened after hormone th…

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…

This phase 1 trial investigates a new treatment for advanced ovarian cancer that has stopped responding to platinum chemotherapy. The therapy uses a patient's own immune cells, called T cells, which are genetically modified in a lab to recognize and attack a protein called TAG72 …

This study looks at two ways to protect the heart and metabolism in men with prostate cancer who are on hormone therapy (ADT). ADT can increase the risk of heart problems. The study compares time-restricted eating (a form of intermittent fasting) and two GLP-1 drugs (semaglutide …

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy and radiation can help women with a rare and aggressive type of cervical cancer called small cell neuroendocrine carcinoma. About 45 women with early to advanced stages of the disease…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study compares a new drug called Rina-S to standard chemotherapy (paclitaxel or doxorubicin) in people with endometrial cancer that has returned or worsened after platinum-based chemo and immunotherapy. About 660 participants will be randomly assigned to receive either Rina-…

This trial tests whether wrapping the nerves around the prostate with a special tissue allograft during surgery can reduce erectile dysfunction and incontinence. 25 men with localized prostate cancer will receive the wrap during nerve-sparing prostate removal. The study focuses o…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…

This trial compares two treatment approaches for men with aggressive, metastatic prostate cancer that has stopped responding to hormone therapy and docetaxel. One approach uses a combination of two chemotherapy drugs (cabazitaxel and carboplatin), while the other uses a radioacti…

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…

This study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…

This phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can slow down cancer growth better than enzalutamide alone. It involves 1000 men with metastatic prostate cancer that still responds to hormone therapy. Participants will be…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This phase III trial tests whether giving an extra round of chemotherapy and immunotherapy (pembrolizumab) before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the cancer growing. About 336 participants will be rando…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase trial tests a new two-drug combination for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The drugs are REGN5678, which helps immune cells target cancer cells, and cemiplimab, which removes the br…

This phase 3 trial is testing whether adding low-intensity shockwave therapy to standard erectile dysfunction pills helps men recover erectile function more effectively after robotic prostate cancer surgery. The study involves 158 men who have undergone nerve-sparing surgery and …

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This Phase 3 trial tests whether adding the experimental drug mevrometostat to the standard drug enzalutamide can slow cancer growth better than enzalutamide alone. It involves 900 men with metastatic castration-resistant prostate cancer who have not yet tried certain hormone the…

This phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…

This Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…

This phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…

This study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…

This trial tests whether tailoring prostate cancer therapy to the genetic makeup of a person's tumor can improve the response before surgery. Men with high-risk localized prostate cancer receive initial hormone therapy while their tumor is genetically analyzed, then are assigned …

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…

This phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive solid tumors (excluding breast cancer). Both drugs block signals that help cancer cells grow. The trial enrolls 70 adults with advanced or recurrent gynecologi…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…

This early-phase trial is testing a combination of two experimental drugs—Pasritamig and ARX517—in 140 men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if the combin…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This study tests a new drug called LBL-024 combined with the chemotherapy paclitaxel in people with ovarian cancer that has become resistant to platinum-based treatments. The trial involves 110 participants and aims to see if the combination can shrink tumors and delay disease pr…

This study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people with ovarian or endometrial cancer that has come back but still responds to platinum-based treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 5…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This early-stage study tests a new drug called JANX007 in men with advanced prostate cancer that has spread and stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 272 men will take part across multiple centers.

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This trial tests two ways of delivering radiation for men with high-risk prostate cancer that has not spread. One approach uses a standard combination of brachytherapy (a temporary radioactive implant) plus SBRT (precise external beams). The other uses SBRT alone. The goal is to …

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This study tests a combination of two drugs—cabozantinib (a targeted therapy) and 177Lu-PSMA-617 (a radioactive drug)—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if the combination can slow cancer gr…

This study is testing an experimental drug called SHR-4298 in 200 people with advanced solid tumors that cannot be removed by surgery or cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow cancer…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…

This early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…

This phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This trial is investigating whether adding radiation therapy to a standard combination of chemotherapy and two targeted drugs can improve outcomes for people with stage IVB cervical cancer. The study combines external beam radiation and internal brachytherapy with cisplatin, pacl…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This phase 3 trial is testing whether a targeted drug (trastuzumab deruxtecan) combined with immunotherapy (rilvegostomig or pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced or recurrent endometrial cancer that has a specific prot…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage study tests a small implant called Enolen that delivers the drug enzalutamide directly into the prostate. The goal is to see if it is safe and how much drug reaches the tumor. About 56 men with prostate cancer who are already scheduled for prostate removal surger…

This trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This phase II study is testing whether women with certain types of early-stage endometrial cancer can safely receive less aggressive treatment after surgery. The approach is guided by the tumor's molecular profile—either POLE-mutated or p53 wildtype/NSMP. Around 393 participants …

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to be…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This trial is testing whether adding surgery to remove the prostate to standard drug therapy helps men with advanced, hormone-sensitive prostate cancer that has spread to multiple sites. Participants will receive either the usual drug treatment alone or the same drugs plus surger…

This early-phase study tests a new drug called HLX3902 in about 48 people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. The drug is designed to help the …

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This early-stage trial is testing a new drug called BMS-986460 in 140 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the right dose, while also looking fo…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-stage study tests BPX-601, a personalized CAR T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has spread and stopped responding to other treatments. The trial will enroll 36 people to find the safest dose and check for side effe…

This early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer…

This study tests whether taking darolutamide (a hormone-blocking pill) plus standard hormone therapy for 12 or 24 weeks before prostate removal surgery can reduce or eliminate cancer in men with high-risk localized prostate cancer. About 250 men in China will be randomly assigned…

This early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This study tests whether eating 2 ounces of walnuts daily for 4-10 weeks can slow prostate cancer growth in 50 men scheduled for prostate removal. Participants are randomly assigned to add walnuts to their usual diet or stick with their normal eating habits. Researchers will meas…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This trial is investigating whether combining an immunotherapy drug (a PD-1 inhibitor like sintilimab or pembrolizumab) with progesterone therapy can help young women with early-stage, mismatch repair-deficient (MMRd) endometrial cancer achieve complete remission while preserving…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This Phase III trial tests whether adding the drug bevacizumab to a standard chemotherapy plus immunotherapy regimen can help people with a specific type of advanced or recurrent endometrial cancer (pMMR, TP53 mutated). About 255 participants will be randomly assigned to one of t…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study tests whether a special 5-day-per-month diet that mimics fasting can improve how well standard prostate cancer treatments work. 138 men with advanced prostate cancer will either follow this diet or eat normally for 6 months. Researchers will measure PSA levels and meta…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This trial asks whether robot-assisted hysterectomy is as effective as traditional open surgery for treating early-stage cervical cancer. About 800 women with stage IB (excluding IB3) or IIA1 cervical cancer will be randomly assigned to one of the two surgical approaches. The mai…

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This phase 3 trial tests whether taking the drug olaparib for one year works as well as taking it for two years to keep ovarian cancer from coming back. The study includes 880 people with advanced ovarian cancer (stage III or IV) who have a BRCA mutation or similar DNA repair pro…

This trial tests a personalized approach to treating advanced solid tumors. Doctors take a patient's own immune cells, train them to recognize that patient's specific cancer mutations, and inject them back under the skin. The goal is to see if these customized cells can safely tr…

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This study compares two treatments for low-to-intermediate risk prostate cancer: a new robotic surgery that removes part of the prostate through a single small incision, and high-intensity focused ultrasound (HIFU) that uses sound waves to destroy cancer cells. About 276 men will…

This phase 2 trial tests whether adding vorinostat to the radioactive drug 177Lu-PSMA-617 can help men with PSMA-low metastatic castration-resistant prostate cancer. The goal is to increase PSMA levels on cancer cells so the radiation therapy works better. About 15 participants w…

This Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…

This study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This trial is testing whether adding the chemotherapy drug docetaxel after standard treatment (radiation or surgery) can improve outcomes for men with a particularly aggressive form of prostate cancer (Gleason score 9-10). Participants will either receive standard treatment alone…

This study tests whether early referral to a cardio-oncology specialist can lower heart risks in prostate cancer patients receiving long-term hormone therapy (ARPI). About 80 men with high-risk or advanced prostate cancer and additional heart risk factors will be assigned to eith…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This early-stage study tests a new drug called AMG 509, alone or with other medicines, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check safety and how the body processes the drug. About 479 participants will…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This early-phase trial is testing a new drug called AZD8421, alone or with other cancer drugs, in people with advanced ER+ breast cancer or high-grade ovarian cancer. The study aims to find safe doses and see if the drug can shrink tumors. About 564 women aged 18 and older will t…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…

This early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take nirapa…

This study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This trial is testing a shorter course of radiation therapy for women who have had surgery for cervical cancer. Instead of the usual many weeks of daily treatments, participants receive a slightly higher dose each day over about three and a half weeks. The goal is to see if this …

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …

This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…

This early-phase trial tests a personalized therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a sample of the patient's tumor, grow them into large numbers in a lab, and infuse them back into the patient. …

This phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This study tests whether a new combination of two drugs, inavolisib and enzalutamide, works better than standard treatments for men with metastatic castration-resistant prostate cancer that has progressed after one prior therapy. About 100 men will be randomly assigned to receive…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study looks at men with high-risk prostate cancer who will receive radiation therapy along with hormone therapy for either 6 months or 18 months. The goal is to see if the shorter treatment works as well at preventing cancer from coming back or getting worse over 5 years. Pa…

This phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…

This Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-phase study is testing a new daily pill called ACE-232 in 67 men with metastatic castration-resistant prostate cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of whether …

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This phase II trial tests a new radiation technique for low to intermediate risk prostate cancer. It uses an MRI-guided 'microboost' to deliver a higher dose to the tumor while lowering the dose to the rest of the prostate. The goal is to see if this approach is safe and causes f…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…

This early-stage trial tests whether an experimental drug called FX-111 is safe enough to study further in men with metastatic castration-resistant prostate cancer (mCRPC), a form of advanced prostate cancer that no longer responds to standard hormone therapy. Participants take F…

This Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…

This phase 3 trial tests whether a denser weekly chemotherapy schedule (carboplatin every 3 weeks plus weekly paclitaxel) can help ovarian cancer patients whose tumors are not responding well to standard treatment. The study enrolls 250 adults with advanced ovarian cancer who hav…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This phase 2 trial is testing whether an investigational oral drug called MRT-2359, when combined with the standard prostate cancer drug apalutamide, can lower PSA levels in men with castration-resistant prostate cancer. The study includes about 25 adults with a specific genetic …

This phase 3 trial tests a radioactive drug called lutetium-177 vipivotide tetraxetan in 450 men whose prostate cancer has returned and spread to a few spots after initial treatment. The drug targets a protein on cancer cells and delivers radiation directly to them. The goal is t…

This early-stage trial is testing whether combining two cancer drugs (lenvatinib and pembrolizumab) with a shorter course of pelvic radiation is safe for people with recurrent or unresectable endometrial cancer. The study aims to find the best dose of lenvatinib when used in this…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This study tests an experimental drug called HRS-7525 in men with advanced prostate cancer. The main goals are to check its safety, find the highest safe dose, and determine the best dose for future studies. Participants take the drug as tablets, and researchers monitor for side …

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This phase III trial is testing whether adding the drug darolutamide and a precise, high-dose radiation technique (SBRT) to standard hormone therapy and radiation can help men with high-risk localized prostate cancer live longer without the cancer spreading. About 700 men will be…

This early-stage trial is testing an experimental oral drug called OATD-02 in people with advanced or metastatic colorectal, ovarian, pancreatic, or renal cell cancer. The goal is to see if the drug is safe and whether it can help the immune system attack tumors by increasing arg…

This phase 2 trial compares two standard hormone therapies for prostate cancer—relugolix (a daily pill) and leuprolide (an injection every three months)—to see how they affect quality of life, cholesterol, and blood sugar. The study enrolls men who need six months of hormone ther…

This trial tests whether placing a small closed-suction drain under the skin before closing the incision can reduce wound complications in women with thick subcutaneous tissue (2.5 cm or more) undergoing midline abdominal surgery for gynecologic cancer. Half of the participants w…

This trial compares two surgical approaches for early-stage cervical cancer: robotic-assisted surgery using the da Vinci system versus traditional open surgery. Researchers are asking whether the minimally invasive robotic method can match or improve upon open surgery in terms of…

This early-stage trial tests an experimental drug called TQB3107, taken as a tablet, in people with advanced malignant tumors. The goal is to find a safe dose and understand how the body processes the drug. TQB3107 is designed to block a specific target inside cancer cells, poten…

This study tests whether giving heated chemotherapy directly into the abdomen during surgery is safe for women aged 70 and older with advanced ovarian cancer. The treatment, called NIPEC with carboplatin, is delivered at normal body temperature for 90 minutes right after the surg…

This early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…

This phase II trial is testing whether a short course of radiation combined with the immunotherapy drug adebrelimab and a single platinum chemotherapy drug can eliminate all signs of cancer before surgery in women with locally advanced cervical cancer. Participants receive the co…

This phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…

This phase 3 trial is testing whether adding an experimental drug called rinzimetostat to the standard drug darolutamide can slow the progression of metastatic castration-resistant prostate cancer better than current treatments. The study enrolls men whose cancer has worsened aft…

This trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…

This trial tests whether the drug rezvilutamide, taken alone for 48 weeks after prostate removal surgery, can prevent cancer from coming back in men at high risk of recurrence. Standard treatment often includes long-term hormone therapy with significant side effects. The study ai…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-phase trial is testing an experimental oral drug called APG-2449 in people with advanced solid tumors, including certain lung cancers, mesothelioma, esophageal cancer, and ovarian cancer. APG-2449 is designed to block several proteins (FAK, ALK, and ROS1) that help can…

This trial tests whether a newer, single-port robotic surgery for prostate cancer can match or beat the standard multi-port approach in helping men recover sexual function. About 480 men with localized prostate cancer will be randomly assigned to one of the two procedures. Resear…

This trial investigates whether high doses of testosterone can shrink tumors in men with metastatic prostate cancer that no longer responds to standard hormone therapy and has mutations in DNA repair genes like ATM or CDK12. Participants receive monthly injections of high-dose te…

This early-phase trial is investigating whether telmisartan, a drug typically used for high blood pressure, can be safely given to men with prostate cancer — either alone or alongside standard chemotherapy. Researchers will also look for signs that the drug damages tumor DNA or b…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This study tests whether adding precise, high-dose radiation (SBRT) to standard second-generation antiandrogen drugs (enzalutamide or abiraterone) can better control prostate cancer that has spread to a few spots and stopped responding to hormone therapy. About 51 men with oligom…

This study investigates whether using magnetic resonance imaging (MRI) instead of standard CT scans to plan radiation therapy can improve treatment accuracy and reduce side effects. It enrolls adults with prostate, liver, or head and neck cancers who need radiation. Researchers w…

This phase 2 study tests a radioactive antibody, Ac-225 rosopatamab tetraxetan, that seeks out and delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The trial aims t…

This trial investigates whether adding the hormone therapy apalutamide to high-precision radiation (SBRT) can drive prostate-specific antigen (PSA) levels extremely low in men with intermediate-risk prostate cancer. Participants receive apalutamide to block testosterone that fuel…

This phase II trial tests the drug abemaciclib in people whose ovarian or endometrial cancer has returned and whose tumors have a specific genetic change (CDK4/6 pathway activation). Abemaciclib is a pill that blocks certain enzymes that cancer cells need to grow. The study will …

This trial tests whether a 3-day low-residue diet can replace a rectal enema for bowel preparation before laparoscopic endometrial cancer surgery. One hundred women scheduled for surgery will be randomly assigned to either the diet or an enema. The study measures how well the sur…

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This study looks at whether providing food assistance—like food boxes and produce vouchers—helps cancer patients who struggle with food insecurity stay on track with their treatment. Researchers will compare patients who receive six months of food support to those who get standar…

This phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…

This study investigates a new treatment approach for locally advanced cervical cancer that combines carbon ion radiotherapy with immunotherapy (anti-PD-1) and chemotherapy. The goal is to see if this triple therapy improves how long patients live without their cancer progressing.…

This study investigates penile transplantation as a way to replace a severely damaged or missing penis with a donor organ, aiming to restore appearance, sensation, and sexual function. It includes men aged 18-69 who have lost their penis due to trauma, surgery, or birth defects. …

This phase 2 trial investigates whether adding stereotactic body radiotherapy (SBRT) to the PARP inhibitor niraparib can improve control of ovarian cancer that has spread to a limited number of new spots after prior PARP inhibitor therapy. Participants will receive SBRT alone or …

This study enrolls 950 men with suspected but undiagnosed prostate cancer who are scheduled for a biopsy. Researchers will compare the accuracy of prostate MRI against a panel of blood and urine biomarkers (PCA3, PSA, TMPRSS2:ERG) in detecting clinically significant prostate canc…

This phase 3 trial is testing a new radioactive imaging agent called 68Ga-NYM032, given as an injection before a PET/CT scan, in 365 men newly diagnosed with prostate cancer. The goal is to see if this scan can accurately detect whether the cancer has spread to pelvic lymph nodes…

This study is testing whether a blood test that measures a substance called miRNA-371 can accurately detect active testicular cancer in people who have already had their primary tumor removed. Researchers will compare the blood test results with surgical findings to see how well …

This study is working on a new, non-invasive test to help rule out uterine cancer in women aged 45 and older who have abnormal bleeding. Researchers will collect samples from 4,500 women to see how well the test detects cancer and identifies benign cases. If successful, it could …

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study is testing whether a new flexible MRI coil can accurately detect significant prostate cancer in 258 men with intermediate or high-risk disease. The goal is to see if this less invasive approach can reduce the number of unnecessary biopsies. Participants will receive bo…

This study is testing whether an artificial intelligence (AI) tool called CAT-OV can accurately identify ovarian cancer on CT scans. Ovarian cancer is often found late, when it's harder to treat, and current screening methods aren't reliable enough. The AI is being trained and te…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study explores whether women can accurately collect their own samples for HPV testing, which could make cervical cancer screening easier and more accessible. The research focuses on minority women who are often under-screened, using community health workers to help with the …

This trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…

This trial is testing a new blood test that measures tiny molecules called microRNAs to help doctors tell the difference between prostate cancer and benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The study will include 500 men who are scheduled f…

This study in Mozambique is testing two new technologies to improve cervical cancer screening and diagnosis. Researchers will compare a rapid HPV test and a special imaging device against standard methods in about 678 women. The goal is to find faster, more accurate ways to detec…

This trial compares two biopsy needles used during prostate biopsies to see if one provides better tissue samples for cancer detection. The new needle is designed to collect more intact tissue per sample, which might improve the accuracy of diagnosing and grading prostate cancer.…

This early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.

This study is testing a new blood test called HeLP™ that looks at proteins in platelets to diagnose prostate cancer. Researchers want to see if it can be a safe and accurate alternative to current tests like PSA, MRI, and biopsy. The study will enroll 300 men suspected of having …

This study tests a new blood and urine test that looks for DNA markers to detect cancer early and identify where it started. Researchers at Mayo Clinic will enroll about 6,150 people, including those with and without cancer. The goal is to see if these tests can accurately find c…

This study is collecting vaginal fluid samples from 4,200 people to develop a new test for endometrial cancer. Participants include those with abnormal uterine bleeding or a recent endometrial cancer diagnosis. The goal is to find biomarkers that could lead to a simple, non-invas…

This study tests a low-cost HPV test that can be done in one visit, so women get results and treatment on the same day. It aims to reduce the number of women lost to follow-up in cervical cancer screening programs. The study will enroll 1,000 women in remote areas of El Salvador.

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This trial tests whether applying vaginal estrogen before a colposcopy helps doctors see the cervix more clearly in women aged 50 and older. As women age, the area where precancerous changes occur can become harder to view, which may lead to missed diagnoses or repeat procedures.…

Urological diseases like kidney stones, prostate cancer, and bladder cancer are common but require expert diagnosis. This study will develop and test an AI assistant called UroAgent that helps doctors make decisions by analyzing patient records and images. Researchers will use 2,…

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…

This trial evaluates a radioactive tracer called 68Ga-DOTA/NOTA-FAPI-04, given as a single injection before a PET/CT scan, to see if it can better identify primary tumors and metastases in people with various cancers. Researchers will measure how strongly the tracer accumulates i…

This study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid …

This trial compares two ways of taking prostate tissue samples in men with suspicious MRI findings: through the rectum (transrectal) or through the skin between the scrotum and anus (transperineal). Both methods use MRI images to guide the biopsy needle. The main goal is to see i…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

This trial tests whether combining a radioactive tracer (18F-rhPSMA-7.3) with PET and multiparametric MRI can better identify clinically significant prostate cancer than MRI alone. Men suspected of having prostate cancer will receive the tracer and undergo imaging before a target…

This study tests whether a new type of MRI scan, called Diffusion Basis Spectrum Imaging (DBSI), can accurately detect clinically significant prostate cancer without the need for a needle biopsy. Researchers will compare DBSI results to standard biopsy findings in 500 men — some …

This study follows men who had a negative prostate cancer screening about five years ago. They will undergo a repeat MRI and PSA test to see if any clinically significant prostate cancers have developed. The goal is to learn whether repeat screening is valuable and how often it s…

This study aims to create an educational tool that helps women and their doctors make informed choices about using a levonorgestrel-releasing intrauterine system (LNG-IUS) to prevent endometrial cancer. Researchers will survey 270 women, both with and without a history of the dis…

This study tests a program called PINPOINT that helps women with obesity or diabetes get screened for cervical cancer. About 20 women who are behind on screening will be offered options like self-collection or a Pap smear. The goal is to see if the program is practical and well-l…

This study looks at two surgeries to reduce ovarian cancer risk in women with BRCA1 gene changes. One surgery removes only the fallopian tubes, while the other removes both tubes and ovaries. Researchers want to see if removing just the tubes works nearly as well at preventing ca…

This study tests whether adding a polygenic risk score (PRS) — a measure based on 313 genetic markers — to the standard CanRisk model can improve breast cancer risk prediction and prevention. About 100 women at increased risk will receive genetic counseling, a blood draw, and the…

This study is testing a program called FOCUS ON US, designed to help sexual and gender minority (LGBTQ+) cancer patients and their caregivers. The program includes five sessions covering topics like family involvement, coping skills, and symptom management. Researchers want to se…

This study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every 3 weeks and undergo regular eye exams before, during, and after treatment…

This study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…

This study looks at whether acupuncture can help young women (ages 15-40) with cancer get their periods back after chemotherapy caused them to stop. About 60 participants will receive acupuncture or usual care. Researchers will measure how many people join and finish the study, a…

This study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …

This study tests whether adding electroacupuncture and ear acupoint pressing beans to a standard opioid painkiller can better relieve severe cancer pain that doesn't respond to usual treatments. About 30 adults with refractory cancer pain will receive the combination for two week…

This pilot trial tests whether a supervised exercise program is safe, helpful, and practical for adults who have had breast or gynecologic cancer. Participants will take part in a 12-week program combining strength and aerobic training under trained guidance. The study focuses on…

This study tests whether expressive writing—reading and writing about positive experiences—can help cancer survivors manage stress. About 414 survivors will participate from home using a computer or smartphone. The goal is to see if this simple activity can lower stress and impro…

This study tests two supportive care programs—meditation and discussion sessions—for people with advanced (stage IV) cancer and their family caregivers. Researchers want to see if these programs can reduce depressive symptoms and improve quality of life. About 400 patient-caregiv…

This study tests whether a small device that sends mild electrical pulses through the skin (TENS) can reduce pain during a prostate biopsy. About 140 men will get either a real TENS device or a fake one, along with standard numbing medicine. The goal is to see if TENS makes the p…

This pilot trial tests an adaptive stepped-care digital intervention to improve sleep in Chinese cancer survivors with mild-to-moderate insomnia. Participants first receive a self-guided web-based CBT-I program or a simple exercise program; those who don't improve may be stepped …

This study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…

This study tests whether a structured nursing program—including patient education, emotional support, and clear communication—can help men feel more resilient and less anxious when undergoing a transrectal prostate biopsy. Around 120 men scheduled for the procedure will receive t…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This study tests whether psilocybin, the active ingredient in magic mushrooms, combined with talk therapy can safely help cancer survivors with depression or anxiety. Twenty adults who have finished cancer treatment and have no brain involvement will receive a single dose of psil…

This study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …

This study tests a program called enCompass Humana, which provides coaching and resources to unpaid caregivers of adults with both cancer and diabetes. The goal is to see if the program is practical and helpful for caregivers, improving their coping skills and reducing loneliness…

This study compares two standard radiation methods—proton therapy and photon therapy—for women with newly diagnosed cervical or endometrial cancer. The goal is to see which approach causes fewer stomach and bowel side effects. About 116 participants will be randomly assigned to o…

This trial tests whether a digital program called E-Mergir can improve sexual and mental well-being in men who have survived prostate cancer. Many survivors face lasting sexual difficulties and emotional distress, yet few have access to tailored support. The program, delivered th…

This study looks at whether giving cancer survivors free healthy food and online cooking lessons can improve their health and well-being. The program is for survivors who struggle to afford food and are treated at a safety-net hospital. Researchers will check if the program is sa…

This study tests a program called CARES that provides cancer patients with integrated screening and stepped care for symptoms like pain and depression. About 1,750 adults with cancer will be randomly assigned to CARES or standard care. The goal is to see if CARES improves quality…

This trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…

This study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that has spread and no longer responds to standard treatments. About 58 participants will receive either CBD or a placebo three times daily for…

This phase 2 trial tests whether guarana, a natural supplement from the Amazon, can reduce fatigue in 86 people with neuroendocrine tumors or gynecologic cancers. Participants take either guarana or a placebo daily for up to 42 days, and researchers measure changes in fatigue usi…

This study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…

This study tests whether a less invasive lymph node procedure (sentinel mapping) can lower the risk of long-term leg swelling compared to standard lymph node removal. About 428 women with stage I endometrial cancer will be followed for 18 months after hysterectomy. The goal is to…

This study looks at whether intermittent fasting (not eating for 16 hours a day, 5 days a week) is safe and doable for people with advanced ovarian cancer who are getting chemotherapy before surgery. Twenty participants will either follow the fasting schedule or standard diet adv…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

This trial tests whether using a weighted blanket during a first cancer infusion (like chemotherapy) can lower anxiety and distress compared to a regular blanket. The idea is that the deep touch pressure from the blanket may calm the nervous system and increase feelings of well-b…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…

This study tests a personalized program called SPOT-ON for cancer patients suffering from severe shortness of breath. Participants will receive a combination of breathing techniques, relaxation methods, posture adjustments, and oxygen-based therapies, either starting early or aft…

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This pilot trial tests whether a mobile app version of a resilience-building program, called mPRISM, is acceptable and helpful for adolescents and young adults recently diagnosed with cancer. The app teaches coping skills like stress management, goal-setting, and reframing negati…

This small study will test whether giving a 15-20 minute massage during infusion therapy can reduce pain and anxiety in women with gynecologic cancer. Twenty-four participants will be randomly assigned to receive either a hand, foot, or neck/shoulder massage or simply talk with t…

This study tests whether a personalized activity coaching program can help women feel less tired during pelvic radiation therapy for endometrial cancer. Sixteen participants will be randomly assigned to receive coaching or usual care. The main goal is to see if the program is pra…

This trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…

This trial tests whether two types of home-based digital cognitive training can help cancer survivors who have memory, attention, or thinking problems after chemotherapy. Participants will use either a computer program (BrainHQ) or a virtual reality cognitive training for 10 week…

This trial tests whether a one-page communication aid can improve how physicians and patients with cancer discuss the diagnosis. The aid, completed before the consultation, summarizes the patient's disclosure preferences and questions. Researchers will compare outcomes like patie…

This trial tests whether a structured telemedicine program — including wearable activity monitors, breathing exercises, and remote physiotherapy — can reduce urinary incontinence after radical prostatectomy for localized prostate cancer. Two hundred men scheduled for surgery will…

This trial tests whether a short virtual program called GOLD can reduce anxiety and boost resilience in caregivers of children recently diagnosed with cancer. About 40 caregivers will either receive the two-hour GOLD session or standard information. The study measures how many ca…

This pilot study tests a hybrid intervention that combines a digital platform (Findhelp.org) with human navigation sessions to help adolescent and young adult cancer survivors manage financial and health-related social needs. Researchers will refine the approach with input from s…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…

This study tests whether adding a geriatric assessment visit to the standard survivorship care plan improves quality of life and satisfaction for adults aged 65 and older who have completed chemotherapy with curative intent. Participants receive either the standard care plan alon…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This study investigates whether measuring whole-body metabolism—how the body uses energy—can reflect the metabolic changes in ovarian tumors and predict how well patients respond to chemotherapy. Researchers will measure resting metabolic rate and other metabolic markers in women…

This study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study looks at whether a special MRI scan (mpMRI) can better monitor prostate cancer in men who choose active surveillance instead of immediate treatment. About 500 men with low-risk prostate cancer will get regular MRIs, biopsies, and blood tests over several years. The goa…

This study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…

This study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…

This study tests a small MRI coil placed inside the sphenoid sinus during pituitary tumor surgery. The goal is to see if it can provide clearer images of tiny tumors that standard MRI often misses. About 70 adults with pituitary tumors will take part. The coil is inserted through…

This study is testing a mobile app called mSaada that helps community health workers educate women, track screening, and send reminders for cervical cancer screening. The trial involves 6,000 women and health workers across 12 health facilities in western Kenya. The goal is to se…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study tracks 500 men aged 30-75 who have specific genetic changes linked to prostate cancer but have not been diagnosed. Researchers will monitor their health over time using yearly exams, blood tests, and MRI scans to understand how these genes affect cancer risk. The goal …

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This research project tracks men treated with a technology called High-Intensity Focused Ultrasound (HIFU) for prostate cancer or an enlarged prostate. The goal is to see how well this treatment controls disease and affects urinary and sexual function over 10 to 20 years. By coll…

This study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…

This study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer cells make the drug radium-223 work better or worse. The goal is to help doctors choose the best treatment for each patient in …

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…

This study asks 300 adolescents and young adults (ages 15-39) who have or had cancer to fill out questionnaires. The goal is to find gaps in education about exercise, sexual health, fertility, finances, and more. No treatment is given—just a survey to help improve future care.

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This pilot study tests whether giving doctors and patients feedback from AI analysis of their consultations can improve how prostate cancer risks are communicated. Men newly diagnosed with localized prostate cancer will have their initial treatment consultations recorded. An AI s…

This study follows 106 men who have had surgery for prostate cancer to see how well they recover bladder control, sexual function, and overall health. Participants will receive standard care plus optional exercise programs. The goal is to better understand recovery timelines and …

This study tests whether a virtual community health educator (vCHE) can increase referrals to cancer clinical trials among diverse populations. Researchers will enroll 2,000 cancer patients and their caregivers across Florida. Participants interact with a computer-based agent tha…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study is testing whether looking at two biological markers (HPV and p53) in early-stage vulvar cancer can help doctors decide the right amount of surgery. Some women may need less surgery, while others may need more. The study will follow 249 participants for 3 years to see …

This study looks at whether a procedure called leukapheresis can collect more circulating tumor cells (CTCs) from the blood than a standard blood draw in men with metastatic prostate cancer. CTCs are cancer cells that break away from the tumor and travel in the bloodstream. The g…

This study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study gathers medical records and leftover tissue samples from up to 2,000 people with low-grade ovarian or peritoneal tumors. The goal is to create a detailed database that helps researchers learn more about these rare cancers and how they are treated. No new drugs or proce…

This study tracks 170 advanced cancer patients receiving anti-VEGF therapies to record side effects and see how the disease responds. Researchers hope to find patterns linking complications to treatment success. The goal is to help doctors better understand and manage these thera…

This study is collecting medical records and lab results from 70 people diagnosed with a rare type of cervical cancer called clear cell carcinoma. Researchers want to understand the cancer's features and molecular profile better. No new treatments or drugs are being tested—this i…

This study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…

This study follows 100 men with low- or very low-risk prostate cancer who choose active surveillance instead of immediate treatment. Researchers will use questionnaires, exams, biopsies, and MRIs every 6 months to 2-3 years to monitor disease progression over 5 years. The goal is…

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This study follows 1,100 adults with rare urinary tract cancers, such as unusual bladder, kidney, testicular, or penile cancers. Researchers will collect medical records, blood and tumor samples, and imaging over many years to understand how these cancers grow and respond to trea…

This study looks at the genetic makeup of advanced endometrial cancer in 500 women in Russia. Researchers will test tumor samples for specific gene changes to see how common they are and what treatments patients receive. The goal is to gather information, not to test a new treatm…

This study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…

This study follows 2,000 men with prostate cancer who have certain gene mutations. Researchers will track their health over many years to see how these genes relate to cancer growth, treatment response, and survival. Participants do not need to visit the hospital regularly; most …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study is observing about 1,715 people with early-stage endometrial cancer to see how often the cancer comes back and how often lymphedema (swelling) happens after standard treatment. Participants will have regular check-ups for 36 months. The goal is to gather real-world dat…

This study is creating a database to track what happens to men with localized prostate cancer who choose cryotherapy (freezing the tumor). Researchers will record side effects and how long it takes for PSA levels to rise again. Up to 1,000 men will be followed over time to gather…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study explores whether a tool called SmartMatch can quickly analyze tumor tissue from standard surgeries or biopsies to suggest personalized treatment options for people with rare, advanced gynecologic cancers. The goal is to see how often SmartMatch can produce a useful tre…

This study looks at how cancer patients view their doctor's compassion, communication, and professionalism when the doctor uses an electronic health record (EHR) during the visit. About 88 adults with cancer will watch videos or fill out questionnaires. The goal is to understand …

This study looks at how well a short course of hormone therapy (ADT) works in men with high-risk prostate cancer that hasn't spread. Researchers use a special PET/CT scan to measure changes in cancer activity before and after treatment. About 50 men will take part, and they will …

This study collects tissue and blood samples from 1,500 people with prostate or bladder cancer that has come back or spread. Researchers will analyze the samples to find genetic changes and other markers that may explain why some cancers stop responding to treatment. The goal is …

This study is trying to understand why some people who get chemotherapy for cancer later develop heart issues, while others don't. Researchers will collect blood samples from 1,000 adults who have had chemotherapy, including those who had heart problems and those who didn't. By s…

This study looks at how people with endometrial cancer find medical information and how satisfied they are with it. Researchers will also ask patients if they'd be interested in using an AI-powered educational tool. The goal is to understand current needs and see if AI could help…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study looks at how a man's age, health conditions like diabetes or high blood pressure, and sexual function before surgery affect the return of erections after nerve-sparing robotic prostatectomy for prostate cancer. Researchers will track 300 patients for a year, collecting…

This study is testing a new AI tool that creates patient-friendly summaries of radiology reports for people with cancer. The goal is to see if these easy-to-read summaries help patients better understand their scan results and reduce the number of questions doctors receive. About…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study looks at whether vitamin D levels in the blood and cervical fluid before treatment can predict how well chemoradiotherapy works for locally advanced cervical cancer. Researchers will measure vitamin D in 100 women undergoing standard treatment and track their response …

This observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insig…

This study is testing a new questionnaire called PRO-AYA, designed to measure quality of life in adolescents and young adults (ages 15-39) with cancer. Researchers want to see if the survey is reliable and accurate, including a Spanish version. 120 participants will fill out the …

This study is testing whether people in early-phase cancer trials will consistently wear a smartwatch and complete weekly symptom surveys on a phone app. Thirty participants will use the devices for 4 weeks. The goal is to see if this approach is practical and acceptable, not to …

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study looks at how much of the radioactive drug Pluvicto reaches tumors and organs in patients whose kidneys or bone marrow are not working well. About 25 people will be enrolled to check for side effects and safety. The goal is to better understand dosing in these patients,…

This study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…

This study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study collects tissue samples, medical data, and family histories from over 1,100 people being screened for colorectal or endometrial cancer. Researchers hope to discover new genes and mechanisms that increase cancer risk, especially in hereditary cancer syndromes. The goal …

This study follows 260 adults newly diagnosed with cancer who have no prior sleep issues. Researchers will track how insomnia develops over the first year, using questionnaires to measure sleep quality and severity. The goal is to understand what factors—like treatment type or em…

This study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effect…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This observational study will follow 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will collect medical records to see how many men achieve very low PSA leve…

This study explores how patients and healthcare providers view the use of genetic risk profiling for prostate cancer in everyday clinical practice. Through interviews, researchers aim to understand the benefits, challenges, and needs associated with receiving and delivering genet…

This study looks at why some older adults with serious conditions like cancer or fractures become vulnerable or frail. Researchers will follow about 1500 patients to find out how common different causes of vulnerability are and how they affect outcomes like survival and quality o…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This observational study tracks 7,000 men and women with cancer to see how treatments like chemotherapy, radiation, and immunotherapy affect fertility. In women, researchers measure a hormone called AMH to gauge ovarian reserve; in men, they analyze sperm quality. The goal is to …

This pilot study tests whether a new type of CT scanner, called photon-counting CT, can clearly show the urethra in prostate cancer patients without inserting a catheter. Currently, catheters are often needed to see the urethra during radiotherapy planning, which can be uncomfort…

This study investigates whether testicular cancer survivors who received cisplatin-based chemotherapy and bone marrow transplant have hidden heart disease that standard checkups might miss. Researchers will use advanced blood tests and CT scans to measure cholesterol, plaque in t…

This study investigates whether SPECT/CT scans can accurately measure the radiation dose delivered to tumors and healthy organs during 177Lu-PSMA-617 (Pluvicto) therapy for metastatic castration-resistant prostate cancer. Researchers will enroll 60 men scheduled for this treatmen…

This study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian ca…

This study tests whether a large language model (a type of AI) can accurately stage prostate cancer by reading Chinese PSMA PET/CT reports. Researchers will compare the AI's staging against expert doctors' assessments using thousands of de-identified reports. The goal is to see i…

This research study collects tissue samples and medical information from people with cancer who are receiving radiation therapy, as well as from healthy volunteers. The goal is to create a long-term resource that scientists can use to study how cancer responds to radiation and to…

This study follows thousands of young adults (aged 18–40) diagnosed with solid tumors to see how their treatment affects organ preservation, fertility, and long-term quality of life. Researchers will compare them with older patients to understand unique needs. The goal is to impr…